2011;4(3):276-282. 163. Piccini JP, Hellkamp AS, Lokhnygina Y, et al. Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial. J Am Heart Assoc. 2014;3(2):e000521. 1192 Evidence-Based Medicine [ 1 5 4 # 5 C H E S T N O V E M B E R 2 0 1 8 ] 164. Shimada YJ, Yamashita T, Koretsune Y, et al. Effects of regional differences in asia on ef cacy and safety of edoxaban compared with warfarin insights from the ENGAGE AF-TIMI 48 Trial. Circ J. 2015;79(12):2560-2567. 165. Van Spall HG, Wallentin L, Yusuf S, et al. Variation in warfarin dose adjustment practice is responsible for differences in the quality of anticoagulation control between centers and countries: an analysis of patients receiving warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation. 2012;126(19):2309-2316. 166. Wallentin L, Lopes RD, Hanna M, et al. Ef cacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial brillation. Circulation. 2013;127(22):2166-2176. 167. Wallentin L, Yusuf S, Ezekowitz MD, et al. Ef cacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial brillation: an analysis of the RE-LY trial. Lancet. 2010;376(9745):975-983. 168. Shore S, Ho PM, Lambert-Kerzner A, et al. Site-level variation in and practices associated with dabigatran adherence. JAMA. 2015;313(14):1443-1450. 169. Violi F, Lip GY, Pignatelli P, Pastori D. Interaction between dietary vitamin K intake and anticoagulation by vitamin K antagonists: is it really true?: A systematic review. Medicine. 2016;95(10):e2895. 170. Pastori D, Pignatelli P, Cribari F, et al. Time to therapeutic range (TtTR), anticoagulation control, and cardiovascular events in vitamin K antagonists-naive patients with atrial brillation. 